CAD-1005 Phase 2 Trial Shows Significant Reduction in Thrombotic Events
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 24 2026
0mins
Should l Buy CVKD?
Source: Newsfilter
- Significant Efficacy: CAD-1005 demonstrated over a 25% absolute reduction in thrombotic events compared to placebo while showing no significant difference in platelet recovery rates, indicating its potential in treating thrombotic conditions.
- Clinical Trial Progress: The randomized, blinded, placebo-controlled trial concluded in December 2025 with a final dataset of 24 patients, supporting CAD-1005 as a first-line treatment for HIT, which could reshape current treatment paradigms.
- FDA Meeting Scheduled: Cadrenal has secured an End-of-Phase 2 meeting with the FDA to align on a Phase 3 registration path for CAD-1005, marking a significant milestone in its development and potentially accelerating its market entry.
- Broad Market Potential: As the only 12-LOX inhibitor in clinical development globally targeting the immune mechanisms of HIT, CAD-1005 addresses a critical unmet medical need, likely providing substantial market opportunities and competitive advantages for the company.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CVKD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CVKD
About CVKD
Cadrenal Therapeutics, Inc. is a biopharmaceutical company developing therapeutics to overcome the limitations of anticoagulation therapy. It has three clinical-stage assets: VLX-1005, a first-in-class Phase 2 12-LOX Inhibitor for patients with HIT; tecarfarin, an oral vitamin K antagonist (VKA) for chronic use in patients with kidney dysfunction or left ventricular assist devices (LVADs), and frunexian, a parenteral small-molecule Factor XIa antagonist for use in acute hospital settings. Its product candidate, tecarfarin, is a late-stage, reversible oral VKA in the same drug class as warfarin, designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Its frunexian is a small molecule fast-on, fast-off parenteral Phase II-ready potent intravenous (IV) Factor XIa inhibitor designed for acute care settings, especially where contact activation of coagulation by medical devices or artificial surfaces plays a significant role.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Life Sciences Virtual Investor Forum Highlights Available On-Demand
- Forum Overview: The Life Sciences Virtual Investor Forum, held on March 11-12, showcased innovative companies from biotechnology, medical devices, and pharmaceuticals, providing investors with insights into emerging technologies and strategic growth opportunities, thereby attracting significant investor interest.
- Presentation Access: Attendees can view forum presentations on-demand for 90 days, available 24/7, which enhances investor-company interaction and improves information transparency in the investment community.
- 1x1 Meeting Requests: Select companies are accepting management meeting requests through March 17, facilitating direct communication between investors and company executives, which strengthens investor relations management.
- Enhanced Investor Engagement: Virtual Investor Conferences provide a real-time interactive platform that allows companies to connect more efficiently with investors, significantly increasing investor engagement and marking an innovation in investor communication methods.
See More
Life Sciences Virtual Investor Forum Agenda Announced
- Agenda Announcement: Virtual Investor Conferences has announced the Life Sciences Virtual Investor Forum scheduled for March 11-12, 2026, inviting individual and institutional investors to participate for free, aiming to broaden the investor base and enhance company-investor interactions.
- Company Presentation Schedule: The forum will feature presentations from several life sciences companies, including SeaStar Medical Holding Corporation and Nasus Pharma Ltd., with one-on-one management meetings arranged to facilitate direct communication of strategies to investors.
- Platform Advantages: The Virtual Investor Conferences provide a real-time investor engagement solution that replicates the components of an on-site investor conference, enabling companies to access investors more efficiently and enhance presentation effectiveness, thereby increasing investor participation.
- Focus on Industry Innovation: The forum highlights innovators in the life sciences sector, with the EVP of OTC Markets Group stating that the conference offers a unique opportunity for companies to engage with a broader investor audience, fostering strategic communication within the industry.
See More
CAD-1005 Phase 2 Trial Shows Significant Reduction in Thrombotic Events
- Significant Efficacy: CAD-1005 demonstrated over a 25% absolute reduction in thrombotic events compared to placebo while showing no significant difference in platelet recovery rates, indicating its potential in treating thrombotic conditions.
- Clinical Trial Progress: The randomized, blinded, placebo-controlled trial concluded in December 2025 with a final dataset of 24 patients, supporting CAD-1005 as a first-line treatment for HIT, which could reshape current treatment paradigms.
- FDA Meeting Scheduled: Cadrenal has secured an End-of-Phase 2 meeting with the FDA to align on a Phase 3 registration path for CAD-1005, marking a significant milestone in its development and potentially accelerating its market entry.
- Broad Market Potential: As the only 12-LOX inhibitor in clinical development globally targeting the immune mechanisms of HIT, CAD-1005 addresses a critical unmet medical need, likely providing substantial market opportunities and competitive advantages for the company.
See More
Cadrenal Advances Anticoagulation Pipeline, VLX-1005 Completes Phase 2 Trial
- Phase 2 Trial Progress: Cadrenal's anticoagulant drug VLX-1005 has completed its Phase 2 clinical trial, with data currently under analysis and expected to be published soon, indicating the company's potential in the anticoagulation sector despite a 4% drop in stock price prior to this announcement.
- FDA Fast Track Designation: VLX-1005 has received both Orphan Drug and Fast Track designations from the FDA, highlighting its potential market value in treating heparin-induced thrombocytopenia (HIT) and likely expediting subsequent regulatory approval processes.
- Market Demand Insight: Approximately 50,000 new HIT cases occur annually in the U.S., underscoring the urgent need for new therapies, with Cadrenal's product poised to fill gaps left by existing anticoagulants, particularly in the context of heparin use during cardiovascular surgeries.
- Other Development Programs: In addition to VLX-1005, Cadrenal is advancing Tecarfarin and Fruinexian, with the former targeting patients with end-stage kidney disease and the latter being a short-acting Factor XI inhibitor for cardiovascular surgery, demonstrating the company's diversified strategic approach in the anticoagulation field.
See More
Cadrenal Acquires VLX-1005 to Strengthen Anticoagulation Pipeline
- Acquisition Strengthens Pipeline: Cadrenal Therapeutics' acquisition of VLX-1005 and related 12-LOX assets immediately enhances its pipeline, addressing a $40 billion anticoagulation market and approximately 56,000 annual HIT diagnoses.
- Optimistic Clinical Outlook: VLX-1005 demonstrated good tolerability in two Phase 1 studies with healthy participants, showing no deaths or serious adverse events, indicating promising potential for application in HIT patients.
- Significant Market Potential: The HIT market is projected to reach $1 billion in the US and EU, and the development of VLX-1005 will help improve patient outcomes, addressing urgent needs in high-risk populations.
- Strategic Investment Returns: The acquisition agreement includes milestone payments and royalties on global sales, ensuring Cadrenal can allocate capital to advance VLX-1005's clinical development, driving long-term growth for the company.
See More
Cadrenal Acquires VLX-1005, Strengthening Anticoagulation Pipeline
- Acquisition Strengthens Pipeline: Cadrenal Therapeutics' acquisition of VLX-1005 and related 12-LOX assets immediately enhances its pipeline, addressing an underserved therapeutic opportunity in the $40 billion anticoagulation market, showcasing the company's strategic positioning in high-risk patient treatment.
- Optimistic Clinical Outlook: As the first selective inhibitor targeting HIT, VLX-1005 has shown favorable safety and tolerability in two Phase 1 studies with healthy participants, with no serious adverse events reported, indicating its potential for clinical application.
- Significant Market Potential: With approximately 56,000 confirmed HIT diagnoses annually in the U.S. and a projected market size of $1 billion, the development of VLX-1005 is poised to significantly improve patient outcomes and meet unmet medical needs.
- Strategic Investment Returns: The acquisition agreement includes milestone payments contingent on future clinical and regulatory achievements, ensuring Cadrenal can effectively allocate capital to advance the clinical development of VLX-1005, enhancing its market competitiveness.
See More
Life Sciences Virtual Investor Forum Highlights Available On-Demand
- Forum Overview: The Life Sciences Virtual Investor Forum, held on March 11-12, showcased innovative companies from biotechnology, medical devices, and pharmaceuticals, providing investors with insights into emerging technologies and strategic growth opportunities, thereby attracting significant investor interest.
- Presentation Access: Attendees can view forum presentations on-demand for 90 days, available 24/7, which enhances investor-company interaction and improves information transparency in the investment community.
- 1x1 Meeting Requests: Select companies are accepting management meeting requests through March 17, facilitating direct communication between investors and company executives, which strengthens investor relations management.
- Enhanced Investor Engagement: Virtual Investor Conferences provide a real-time interactive platform that allows companies to connect more efficiently with investors, significantly increasing investor engagement and marking an innovation in investor communication methods.
See More
Life Sciences Virtual Investor Forum Agenda Announced
- Agenda Announcement: Virtual Investor Conferences has announced the Life Sciences Virtual Investor Forum scheduled for March 11-12, 2026, inviting individual and institutional investors to participate for free, aiming to broaden the investor base and enhance company-investor interactions.
- Company Presentation Schedule: The forum will feature presentations from several life sciences companies, including SeaStar Medical Holding Corporation and Nasus Pharma Ltd., with one-on-one management meetings arranged to facilitate direct communication of strategies to investors.
- Platform Advantages: The Virtual Investor Conferences provide a real-time investor engagement solution that replicates the components of an on-site investor conference, enabling companies to access investors more efficiently and enhance presentation effectiveness, thereby increasing investor participation.
- Focus on Industry Innovation: The forum highlights innovators in the life sciences sector, with the EVP of OTC Markets Group stating that the conference offers a unique opportunity for companies to engage with a broader investor audience, fostering strategic communication within the industry.
See More
CAD-1005 Phase 2 Trial Shows Significant Reduction in Thrombotic Events
- Significant Efficacy: CAD-1005 demonstrated over a 25% absolute reduction in thrombotic events compared to placebo while showing no significant difference in platelet recovery rates, indicating its potential in treating thrombotic conditions.
- Clinical Trial Progress: The randomized, blinded, placebo-controlled trial concluded in December 2025 with a final dataset of 24 patients, supporting CAD-1005 as a first-line treatment for HIT, which could reshape current treatment paradigms.
- FDA Meeting Scheduled: Cadrenal has secured an End-of-Phase 2 meeting with the FDA to align on a Phase 3 registration path for CAD-1005, marking a significant milestone in its development and potentially accelerating its market entry.
- Broad Market Potential: As the only 12-LOX inhibitor in clinical development globally targeting the immune mechanisms of HIT, CAD-1005 addresses a critical unmet medical need, likely providing substantial market opportunities and competitive advantages for the company.
See More
Cadrenal Advances Anticoagulation Pipeline, VLX-1005 Completes Phase 2 Trial
- Phase 2 Trial Progress: Cadrenal's anticoagulant drug VLX-1005 has completed its Phase 2 clinical trial, with data currently under analysis and expected to be published soon, indicating the company's potential in the anticoagulation sector despite a 4% drop in stock price prior to this announcement.
- FDA Fast Track Designation: VLX-1005 has received both Orphan Drug and Fast Track designations from the FDA, highlighting its potential market value in treating heparin-induced thrombocytopenia (HIT) and likely expediting subsequent regulatory approval processes.
- Market Demand Insight: Approximately 50,000 new HIT cases occur annually in the U.S., underscoring the urgent need for new therapies, with Cadrenal's product poised to fill gaps left by existing anticoagulants, particularly in the context of heparin use during cardiovascular surgeries.
- Other Development Programs: In addition to VLX-1005, Cadrenal is advancing Tecarfarin and Fruinexian, with the former targeting patients with end-stage kidney disease and the latter being a short-acting Factor XI inhibitor for cardiovascular surgery, demonstrating the company's diversified strategic approach in the anticoagulation field.
See More
Cadrenal Acquires VLX-1005 to Strengthen Anticoagulation Pipeline
- Acquisition Strengthens Pipeline: Cadrenal Therapeutics' acquisition of VLX-1005 and related 12-LOX assets immediately enhances its pipeline, addressing a $40 billion anticoagulation market and approximately 56,000 annual HIT diagnoses.
- Optimistic Clinical Outlook: VLX-1005 demonstrated good tolerability in two Phase 1 studies with healthy participants, showing no deaths or serious adverse events, indicating promising potential for application in HIT patients.
- Significant Market Potential: The HIT market is projected to reach $1 billion in the US and EU, and the development of VLX-1005 will help improve patient outcomes, addressing urgent needs in high-risk populations.
- Strategic Investment Returns: The acquisition agreement includes milestone payments and royalties on global sales, ensuring Cadrenal can allocate capital to advance VLX-1005's clinical development, driving long-term growth for the company.
See More
Cadrenal Acquires VLX-1005, Strengthening Anticoagulation Pipeline
- Acquisition Strengthens Pipeline: Cadrenal Therapeutics' acquisition of VLX-1005 and related 12-LOX assets immediately enhances its pipeline, addressing an underserved therapeutic opportunity in the $40 billion anticoagulation market, showcasing the company's strategic positioning in high-risk patient treatment.
- Optimistic Clinical Outlook: As the first selective inhibitor targeting HIT, VLX-1005 has shown favorable safety and tolerability in two Phase 1 studies with healthy participants, with no serious adverse events reported, indicating its potential for clinical application.
- Significant Market Potential: With approximately 56,000 confirmed HIT diagnoses annually in the U.S. and a projected market size of $1 billion, the development of VLX-1005 is poised to significantly improve patient outcomes and meet unmet medical needs.
- Strategic Investment Returns: The acquisition agreement includes milestone payments contingent on future clinical and regulatory achievements, ensuring Cadrenal can effectively allocate capital to advance the clinical development of VLX-1005, enhancing its market competitiveness.
See More
